# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001367644-23-000002
Filing Date
2023-01-05
Accepted
2023-01-05 17:27:31
Documents
15
Period of Report
2023-01-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | ebs-20230105.htm iXBRL | 8-K | 36889
2 | EX-99.1 | emergentbiosolutionssign.htm | EX-99.1 | 7496
6 | GRAPHIC | emergentbiosolutionssign001.jpg | GRAPHIC | 296265
7 | GRAPHIC | emergentbiosolutionssign002.jpg | GRAPHIC | 205505
| Complete submission text file | 0001367644-23-000002.txt |  | 880623

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
3 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | ebs-20230105.xsd | EX-101.SCH | 1965
4 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | ebs-20230105_lab.xml | EX-101.LAB | 25154
5 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | ebs-20230105_pre.xml | EX-101.PRE | 13100
9 | EXTRACTED XBRL INSTANCE DOCUMENT | ebs-20230105_htm.xml | XML | 11453

Mailing Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879
Business Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 23512541
SIC: 2834 Pharmaceutical Preparations